Yimmugo is under clinical development by Biotest and currently in Phase III for Primary Immune Deficiency (PID). According to GlobalData, Phase III drugs for Primary Immune Deficiency (PID) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Yimmugo’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Yimmugo overview
Human immunoglobulin (Yimmugo) is an immune sera and immunoglobulin preparation. It is formulated as solution for intravenous route of administration. Yimmugo is indicated for the treatment of primary immunodeficiency syndromes (PID) with impaired antibody production, secondary immunodeficiency (SID), primary immune thrombocytopenia (ITP) in patients at high risk of bleeding or before surgical interventions to correct the platelet count, Guillain-Barre syndrome, Kawasaki syndrome, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Multifocal motor neuropathy (MMN).
BT-595 is under development for the treatment of primary immune deficiency (PID), idiopathic thrombocytopenic purpura and scleromyxedema (dermatology). It is administered by intravenous route as solution. The drug candidate is a polyvalent human immunoglobulin.
Biotest overview
Biotest, a subsidiary of Grifols SA, provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products include clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, haematology, and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East, and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary and Spain and Brazil. Biotest is headquartered in Dreieich, Hessen, Germany.
For a complete picture of Yimmugo’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
